"JPMorgan sees Hims & Hers as a leading direct-to-consumer healthcare platform with 2.5 million subscribers across various health sectors, including weight loss and women's health. The multi-specialty model and international presence provide defensible scale advantages."
"The Novo Nordisk partnership removes significant legal overhang and positions Hims & Hers as a platform offering branded, generic, and compounded products, legitimizing the GLP-1 business and widening the addressable market."
"Hims & Hers closed fiscal 2025 with $2.35 billion in revenue, a 59% increase year over year, and expects full-year 2026 revenue between $2.7 billion and $2.9 billion, with adjusted EBITDA of $300 million to $375 million."
JPMorgan analyst Cory Carpenter initiated coverage of Hims & Hers Health with an Overweight rating and a $35 price target. The partnership with Novo Nordisk is seen as a turning point for the telehealth platform. Hims & Hers has 2.5 million subscribers and offers various healthcare services. The Novo Nordisk deal alleviates legal concerns and expands the market for Hims & Hers. The company reported $2.35 billion in revenue for fiscal 2025 and expects growth in 2026, supported by acquisitions and international expansion.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]